IL317141A - Oleic acid-conjugated oligonucleotides and uses thereof - Google Patents
Oleic acid-conjugated oligonucleotides and uses thereofInfo
- Publication number
- IL317141A IL317141A IL317141A IL31714124A IL317141A IL 317141 A IL317141 A IL 317141A IL 317141 A IL317141 A IL 317141A IL 31714124 A IL31714124 A IL 31714124A IL 317141 A IL317141 A IL 317141A
- Authority
- IL
- Israel
- Prior art keywords
- oligonucleotide molecule
- oleic acid
- molecule
- seq
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22382493.9A EP4282964A1 (en) | 2022-05-23 | 2022-05-23 | Oligonucleotides conjugated to oleic acid and uses thereof |
| PCT/EP2023/063829 WO2023227622A1 (en) | 2022-05-23 | 2023-05-23 | Oligonucleotides conjugated to oleic acid and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317141A true IL317141A (en) | 2025-01-01 |
Family
ID=81941129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317141A IL317141A (en) | 2022-05-23 | 2023-05-23 | Oleic acid-conjugated oligonucleotides and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12116575B2 (https=) |
| EP (3) | EP4282964A1 (https=) |
| JP (2) | JP2025522282A (https=) |
| CN (1) | CN119816594A (https=) |
| AU (1) | AU2023277730A1 (https=) |
| CA (1) | CA3255781A1 (https=) |
| IL (1) | IL317141A (https=) |
| TW (1) | TW202411424A (https=) |
| WO (1) | WO2023227622A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282964A1 (en) * | 2022-05-23 | 2023-11-29 | Universitat de Valéncia | Oligonucleotides conjugated to oleic acid and uses thereof |
| WO2025114442A1 (en) * | 2023-11-28 | 2025-06-05 | Arthex Biotech S.L. | Oligonucleotides conjugated to oleic acid and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| US10077443B2 (en) * | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| ES3047792T3 (en) * | 2014-07-14 | 2025-12-04 | Univ California | Crispr/cas transcriptional modulation |
| WO2016201272A1 (en) * | 2015-06-12 | 2016-12-15 | King Abdulaziz City For Science And Technology | Method of diagnosing patients with conditions caused by mendelian mutations |
| JP7511326B2 (ja) * | 2015-10-09 | 2024-07-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物およびその方法 |
| ES2659845B1 (es) | 2016-09-19 | 2019-01-04 | Univ Valencia | Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello |
| TW202019441A (zh) * | 2018-07-20 | 2020-06-01 | 美商雷格勒斯治療公司 | 用於經口遞送寡核苷酸之方法 |
| EP4081302A4 (en) | 2019-12-23 | 2025-01-29 | University Of Massachusetts | OLIGONUCLEOTIDES FOR TISSUE-SPECIFIC GENE EXPRESSION MODULATION |
| EP4282964A1 (en) * | 2022-05-23 | 2023-11-29 | Universitat de Valéncia | Oligonucleotides conjugated to oleic acid and uses thereof |
-
2022
- 2022-05-23 EP EP22382493.9A patent/EP4282964A1/en not_active Withdrawn
-
2023
- 2023-05-23 CN CN202380056273.5A patent/CN119816594A/zh active Pending
- 2023-05-23 EP EP23724333.2A patent/EP4486891A1/en active Pending
- 2023-05-23 WO PCT/EP2023/063829 patent/WO2023227622A1/en not_active Ceased
- 2023-05-23 TW TW112119205A patent/TW202411424A/zh unknown
- 2023-05-23 EP EP23174951.6A patent/EP4282966A1/en active Pending
- 2023-05-23 AU AU2023277730A patent/AU2023277730A1/en active Pending
- 2023-05-23 US US18/322,487 patent/US12116575B2/en active Active
- 2023-05-23 JP JP2024569113A patent/JP2025522282A/ja active Pending
- 2023-05-23 JP JP2023084942A patent/JP7663873B2/ja active Active
- 2023-05-23 IL IL317141A patent/IL317141A/en unknown
- 2023-05-23 CA CA3255781A patent/CA3255781A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12116575B2 (en) | 2024-10-15 |
| EP4282966A1 (en) | 2023-11-29 |
| US20230407305A1 (en) | 2023-12-21 |
| TW202411424A (zh) | 2024-03-16 |
| JP2025522282A (ja) | 2025-07-15 |
| JP7663873B2 (ja) | 2025-04-17 |
| CN119816594A (zh) | 2025-04-11 |
| EP4282964A1 (en) | 2023-11-29 |
| JP2023172954A (ja) | 2023-12-06 |
| CA3255781A1 (en) | 2023-11-30 |
| EP4486891A1 (en) | 2025-01-08 |
| AU2023277730A1 (en) | 2025-01-02 |
| WO2023227622A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020257111B2 (en) | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy | |
| IL317141A (en) | Oleic acid-conjugated oligonucleotides and uses thereof | |
| JPWO2023022229A5 (https=) | ||
| JP2018516091A5 (https=) | ||
| CN110846316A (zh) | 在基因沉默中具有降低的脱靶效应的una寡聚物 | |
| US20220160880A1 (en) | Antisense nucleic acid targeting pcsk9 | |
| US20250163419A1 (en) | Therapeutic compositions for treating pain via multiple targets | |
| JPWO2021188390A5 (https=) | ||
| JPWO2021119226A5 (https=) | ||
| US20240209377A1 (en) | Therapeutic compositions for treating pain via multiple targets | |
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| WO2024212954A1 (zh) | 抑制lpa基因表达的化合物、药物组合物及其用途 | |
| CN118512601B (zh) | 双链核酸-半乳糖胺-胆固醇化合物及其应用 | |
| JP2019134706A (ja) | デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド | |
| HK40078359A (en) | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy | |
| HK40111629A (zh) | 苏糖核酸反义寡核苷酸及其方法 | |
| US20230212572A1 (en) | Guanosine Analogues for Use in Therapeutics Polynucleotides | |
| US20030099959A1 (en) | Cooperative oligonucleotides | |
| WO2020007889A1 (en) | Antisense oligonucleotides targeting stat1 | |
| HK1203835B (en) | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |